Category: Market/Novel Tech

Month: 01 Oct 2014

Issue: not yet available

Ophthotech Corporation (Nasdaq:OPHT) receives $50M milestone payment from Novartis for clinical progression of Fovista

Ophthotech Corporation (Nasdaq:OPHT) has announced the triggering of a $50 million enrollment milestone payment from Novartis as part of a licensing and commercialization agreement focused on the clinical development of the Ophthotech’s lead compound (“Fovista”) for wet AMD. The payment from Novartis fell due as a result of Ophthotech reaching the first enrollment milestone under the companies’ agreement for a pivotal, multi-national Fovista phase III clinical study and, according to Ophthotech, is the first of a total of $130 million in potential enrollment-based milestones. The compound is expected to be used in combination with anti-VEGF therapy for the treatment of wet AMD.

Back to previous

Related News

Gearoid Tuohy

editor

by Dr. Gearóid Tuohy   Dear EURETINA Members,   A very warm welcome to the December 4th, 2017 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is […]